文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

二甲双胍延长早产型子痫前期妊娠期的随机双盲安慰剂对照试验

Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial.
PubMed 文献 · BMJ · 2021-09-22

该随机双盲安慰剂对照试验在南非开普敦的转诊医院纳入180名孕26+0至31+6周的早产型子痫前期孕妇,随机接受每日3g缓释二甲双胍或安慰剂直至分娩。主要结局为妊娠延长,二甲双胍组从随机化到分娩的中位时间为17.7天,安慰剂组为10.1天,中位差7.6天(几何均数比1.39,95%CI 0.99-1.95;P=0.057)。在持续服药和足量服药亚组中妊娠延长更明显,且未观察到与试验药物相关的严重不良事件。

要点

  • 缓释二甲双胍可能延长早产型子痫前期孕妇的妊娠期,但主要分析未达统计学显著性。
  • 持续服药或足量服药者妊娠延长更显著,提示剂量与依从性可能影响疗效。
  • 二甲双胍组腹泻更常见,但未观察到与试验药物相关的严重不良事件。

核心结论

  • 本试验提示缓释二甲双胍可延长早产型子痫前期孕妇的妊娠期,但仍需进一步试验验证。
  • 该研究为早产型子痫前期治疗提供了概念验证。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在南非开普敦的转诊医院进行。
  • 纳入180名孕26+0至31+6周、接受期待治疗的早产型子痫前期孕妇,随机分为二甲双胍组90人和安慰剂组90人。
  • 干预为每日口服3g缓释二甲双胍或安慰剂,分次服用,直至分娩。

主要发现

  • 从随机化到分娩的中位时间:二甲双胍组17.7天(四分位距5.4-29.4天;n=89),安慰剂组10.1天(3.7-24.1天;n=90),中位差7.6天(几何均数比1.39,95%CI 0.99-1.95;P=0.057)。
  • 在持续服用试验药物任何剂量的亚组中,二甲双胍组中位妊娠延长17.5天(四分位距5.4-28.7天;n=76),安慰剂组7.9天(3.0-22.2天;n=74),中位差9.6天(几何均数比1.67,95%CI 1.16-2.42)。
  • 在服用全剂量亚组中,二甲双胍组中位妊娠延长16.3天(四分位距4.8-28.8天;n=40),安慰剂组4.8天(2.5-15.4天;n=61),中位差11.5天(几何均数比1.85,95%CI 1.14-2.88)。
  • 复合母体、胎儿和新生儿结局以及可溶性fms样酪氨酸激酶-1、胎盘生长因子和可溶性内皮糖蛋白的循环浓度无差异。
  • 二甲双胍组出生体重非显著性增加,新生儿监护室住院时间缩短;未观察到与试验药物相关的严重不良事件,但腹泻在二甲双胍组更常见。

临床怎么用

  • 对于孕26+0至31+6周的早产型子痫前期孕妇,在期待治疗基础上可考虑使用缓释二甲双胍以延长妊娠,但需权衡腹泻等不良反应。
  • 用药期间应关注依从性和剂量,持续足量服药者妊娠延长更明显。
  • 目前证据尚不足以改变常规实践,需等待进一步试验证实。

局限性

  • 主要结局未达到统计学显著性(P=0.057)。
  • 亚组分析(持续服药和足量服药)样本量较小,结果需谨慎解读。
  • 单中心研究,结果外推需谨慎。
  • 原文未报告盲法实施细节和失访情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether extended release metformin could be used to prolong gestation in women being expectantly managed for preterm pre-eclampsia. DESIGN: Randomised, double blind, placebo controlled trial. SETTING: Referral hospital in Cape Town, South Africa. PARTICIPANTS: 180 women with preterm pre-eclampsia between 26+0 to 31+6 weeks' gestation undergoing expectant management: 90 were randomised to extended release metformin and 90 to placebo. INTERVENTION: 3 g of oral extended release metformin or placebo daily, in divided doses, until delivery. MAIN OUTCOME MEASURE: The primary outcome was prolongation of gestation. RESULTS: Of 180 participants, one woman delivered before taking any trial drug. The median time from randomisation to delivery was 17.7 days (interquartile range 5.4-29.4 days; n=89) in the metformin arm and 10.1 (3.7-24.1; n=90) days in the placebo arm, a median difference of 7.6 days (geometric mean ratio 1.39, 95% confidence interval 0.99 to 1.95; P=0.057). Among those who continued to take the trial drug at any dose, the median prolongation of gestation in the metformin arm was 17.5 (interquartile range 5.4-28.7; n=76) days compared with 7.9 (3.0-22.2; n=74) days in the placebo arm, a median difference of 9.6 days (geometric mean ratio 1.67, 95% confidence interval 1.16 to 2.42). Among those who took the full dosage, the median prolongation of gestation in the metformin arm was 16.3 (interquartile range 4.8-28.8; n=40) days compared with 4.8 (2.5-15.4; n=61) days in the placebo arm, a median difference of 11.5 days (geometric mean ratio 1.85, 95% confidence interval 1.14 to 2.88). Composite maternal, fetal, and neonatal outcomes and circulating concentrations of soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin did not differ. In the metformin arm, birth weight increased non-significantly and length of stay decreased in the neonatal nursery. No serious adverse events related to trial drugs were observed, although diarrhoea was more common in the metformin arm. CONCLUSIONS: This trial suggests that extended release metformin can prolong gestation in women with preterm pre-eclampsia, although further trials are needed. It provides proof of concept that treatment of preterm pre-eclampsia is possible. TRIAL REGISTRATION: Pan African Clinical Trial Registry PACTR201608001752102 https://pactr.samrc.ac.za/.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Cluver CA, Hiscock R, Decloedt EH, et al. Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. BMJ. 2021. PMID: 34551918. doi:10.1136/bmj.n2103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。